Table of Content

1. Introduction to FGFR Inhibitors
1.1 Overview
1.2 Evolution of FGFR Inhibitors


2. FGFR Inhibitors - Mechanism of Action


3. Role of FGFR Inhibitors in Cancer Therapy
3.1 AZD4547
3.2 E7090
3.3 Debio 1347
3.4 Futibatinib
3.5 Rogaratinib
3.6 Derazantinib
3.7 RLY-4008
3.8 CPL304110


4. Global FGFR Inhibitor Market Analysis
4.1 Current Market Scenario
4.2 Future Market Opportunity


5. Global FGFR Inhibitors Market Opportunity by Region
5.1 US
5.2 Europe
5.3 Japan
5.4 Rest of World


6. Global FGFR Inhibitors Market Opportunity by Cancer
6.1 Cholangiocarcinoma
6.2 Urothelial Carcinoma
6.3 Lymphoma
6.4 Lung Cancer


7. Balversa - First Approved FGFR Inhibitor 2019
7.1 Overview
7.2 Patent Insight


8. Balversa - Comercial Availability, Dosage & Price Analysis


9. Pemazyre - Second Approved FGFR Inhibitor 2020
9.1 Overview
9.2 Patent Insight


10. Pemazyre - Commercial Information
10.1 Dosage & Price Analysis
10.2 Sales Analysis


11. Truseltiq - Third Approved FGFR Inhibitor Drug 2021
11.1 Overview
11.2 Patent Insight


12. Truseltiq - Commercial Availability, Dosage & Price Analysis


13. Global Sales Forecast - 2021 Till 2026
13.1 Belvesra
13.2 Pemazyre
13.3 Truseltiq


14. FGFR Inhibitors – Ongoing Clinical Trials
14.1 By Phase
14.2 By Development Status
14.3 By Region



15. Global - FGFR Inhibitors in Clinical Trials
15.1 Research
15.2 Preclinical
15.3 Phase-I
15.4 Phase-I/II
15.5 Phase-II
15.6 Phase-II/III
15.7 Phase-III
15.8 Preregistration


16. Marketed FGFR Inhibitors Drugs Clinical Insight


17. Global FGFR Inhibitors Market Dynamics
17.1 Drivers for Global FGFR Inhibitors Market
17.2 Global FGFR Inhibitors Market Challenges


18. Global FGFR Inhibitors Market Future Outlook


19. Competitive Landscape
19.1 Amgen
19.2 Astex Pharmaceuticals
19.3 AstraZeneca
19.4 Bayer
19.5 Blueprint Medicine
19.6 Boehringer Ingelheim International
19.7 Bristol Mayer Squibb
19.8 Incyte Corporation
19.9 Janssen Pharmaceuticals
19.10 Novartis International
19.11 Pfizer Inc
19.12 Roche
19.13 Taiho
19.14 TransThera Biosciences



List of Tables

Table 6-1: Global - Estimated Adoption Rates for Cholangiocarcinoma Targeting FGFR Inhibitors, 2021-2026
Table 6-2: Global - Estimated Adoption Rates for Cholangiocarcinoma Targeting FGFR Inhibitors, 2021-2026
Table 6-3: Global - Estimated Adoption Rates for NHL Targeting FGFR Inhibitors, 2021-2026
Table 6-4: Global - Estimated Adoption Rates for Lung Cancer Targeting FGFR Inhibitors, 2021-2026